Back Hepatitis C

Hepatitis C

EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis

Leaders of liver disease associations from Europe, the U.S., Latin America, and Asia released a Joint Society Statement on Elimination of Viral Hepatitis at the opening session of the International Liver Congress (EASL 2016) this week in Barcelona, calling for enhanced efforts to diagnose and treat hepatitis B and C, with the goal of eliminating viral hepatitis as a public health threat.

alt

EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.

alt

CROI 2016: Advances in Hepatitis C Research [VIDEO]

Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.

alt

 

EASL 2016: International Liver Congress Underway this Week in Barcelona

The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.

alt

Hepatitis C Epidemic in North America Peaked Between 1940 and 1965

The spread of hepatitis C virus (HCV) in North America peaked between 1940 and 1965, according to research published in the March 30 advance edition of Lancet Infectious Diseases. The investigators attribute the rapid spread of the infection to hospital transmissions and reuse of medical injection equipment rather than risky behaviors such as injection drugs, unsafe tattooing, and unprotected sex.

alt

Hepatitis B and C Transmission Could Be Ended in the U.S., Report Says

Hepatitis B and C could be eliminated as a public health threat in the U.S. by treating more people in order to end transmission and prevent progression of liver disease and death, according to a new report from the National Academies of Sciences, Engineering, and Medicine (formerly the Institute of Medicine).

alt

U.S. Government Releases New Guidance for Syringe Program Funding

The U.S. Department of Health and Human Services (DHHS) has released new guidance regarding use of federal funds to pay for many aspects of syringe service programs aimed at reducing the risk of HIV and viral hepatitis transmission among people who inject drugs. The guidance follows a change in federal law that lifts the overall ban on syringe service funding, although the new rules do not allow programs to pay for needles or syringes themselves.

alt

CROI 2016: Hepatitis C [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

 

CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C

Direct-acting antiviral therapy for hepatitis C delivered by non-specialists such as primary care physicians and nurse practitioners is safe and effective -- even for the most difficult-to-treat patients -- and could potentially help increase the number of people receiving treatment, according to findings from the ASCEND study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.

alt